title: Expert Nordic perspectives on the potential of novel inhalers to overcome unmet needs in the management of obstructive lung disease.
abstract: The effective self-management of obstructive lung disease is dependent upon the patient achieving good inhaler technique. However, many current inhalers are complicated to use, which may lead to handling difficulties. These difficulties can cause clinically relevant errors, whereby pharmacotherapy fails to achieve adequate lung deposition and therapeutic effect. In this report, the potential of novel inhaler devices to overcome unmet needs in the management of obstructive lung disease is considered by a panel of Nordic experts. The panel concludes that innovative inhalers can contribute to good disease management and better use of healthcare resources.
authors.affiliation: Department of Respiratory Medicine, Aarhus County Hospital, Aarhus, Denmark; aloekke@gmail.com.
authors.forename: Anders
authors.initials: A
authors.lastname: Løkke
authors.affiliation: Allergy Centre University Hospital, Linköping and Respiratory System Drug Committee at Region Östergötland, Linköping, Sweden.
authors.forename: Lars
authors.initials: L
authors.lastname: Ahlbeck
authors.affiliation: Department of Respiratory Medicine and Allergology, Institute of Clinical Science, Lund University, Lund, Sweden.
authors.forename: Leif
authors.initials: L
authors.lastname: Bjermer
authors.affiliation: Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Denmark.|Department of Medicine, National Hospital, Torshavn, Faroe Islands.
authors.forename: Jann
authors.initials: J
authors.lastname: Mortensen
authors.affiliation: Gransdalen Health Care Centre, Oslo, Norway.
authors.forename: Anders
authors.initials: A
authors.lastname: Østrem
authors.affiliation: Summaryx Ltd, HTA Research, Helsinki, Finland.
authors.forename: Iris
authors.initials: I
authors.lastname: Pasternack
authors.affiliation: TEVA Pharmaceuticals, Helsingborg, Sweden.
authors.forename: Guilherme
authors.initials: G
authors.lastname: Safioti
authors.affiliation: TEVA Pharmaceuticals BV, Amsterdam, the Netherlands.
authors.forename: Saku
authors.initials: S
authors.lastname: Torvinen
keywords: COPD; access; asthma; choice; cost; dry powder inhaler; economic; innovation; medication errors; metered dose inhaler; obstructive lung disease; outcome; patient compliance; patient preference; price; reimbursement; substitution